All the latest worldwide HIV and AIDS news, including treatment, prevention, and hepatitis and TB co-infections. News from our own team of writers plus articles we have selected from other sources.

aidsmap hiv & aids news


← First12345...837Next →

hiv & aids news selected from other sources

  • Neurological and cognitive problems
    Hep C and Substance Abuse May Exacerbate Brain Declines in People With HIV
    Poz | 17 August 2018

    A major mitigating factor may be treating HIV with antiretrovirals.

  • New and experimental HIV treatments
    New HIV therapy reduces virus, boosts immunity in drug-resistant patients
    Science Daily | 16 August 2018

    Ibaluzimab, a CD4 receptor inhibitor and the first monoclonal antibody developed as an anti-HIV drug, was approved for treatment in the US for people with multiply drug-resistant HIV (MDR-HIV) last February. In the results of a phase III study published today, 83% of a group of patients with MDR-HIV achieved an undetectable viral load on ibaluzimab and 50% maintained this over six months. Details of this and another phase III study will be presented later htis year.

  • Epidemiology
    The final frontier in the fight against Aids? There is still one region where HIV infection rates are on the rise
    Daily Telegraph | 16 August 2018

    Huge global progress has been made in tackling an epidemic which has claimed over 35 million lives since the 1980s. But there’s one region in the world where infection rates from the human immunodeficiency virus (HIV) – the pathogen that causes Aids – have been quietly rising in recent years. The HIV crisis in eastern Europe and central Asia – which gathered pace in the two decades following the disintegration of the Soviet Union in 1991 – has now reached epidemic proportions.

  • New and experimental HIV treatments
    Should Gilead Be Worried About This New Monthly HIV Medication?
    Motley Fool | 16 August 2018

    Yesterday, Johnson & Johnson and ViiV Healthcare announced positive results from the Atlas phase 3 study testing their two-drug HIV treatment containing an investigational drug cabotegravir and rilpivirine, a nucleoside reverse transcriptase inhibitor (NRTI) sold by Johnson & Johnson as Edurant. The important thing here isn't going from three medications to two, but that ViiV and Johnson & Johnson's cabotegravir and rilpivirine combination is injected once a month compared to a daily therapy for the three-drug combination.

  • PrEP
    HIV drug research in Wales to cut infection risk
    BBC | 16 August 2018

    Nearly 400 people have been taking part in a three-year trial of the drugs in Wales since last summer. Cardiff University will now examine how people have been taking the medicine - and if that affects the protection.

  • PrEP
    Privilege and Profit Corrupt the PrEP Access Debate
    Poz | 15 August 2018

    If most folks are getting their PrEP for free, then who cares what Gilead charges? Peter Staley explains why ALL of us should care.

  • New and experimental HIV treatments
    ViiV, Janssen’s two-drug HIV regimen hits PhIII targets
    Pharma Times | 15 August 2018

    ViiV Healthcare and Janssen have unveiled positive headline data from a late-stage trial of their injectable two-drug regimen for the treatment of HIV.

  • Treatment for women
    Lynne Mofenson, M.D., Explains the Dolutegravir Risks for People With HIV Who Want to Get Pregnant
    The Body PRO | 15 August 2018

    Lynn Mofenson, M.D., who is a researcher with the Elizabeth Glaser Pediatric AIDS Foundation, explains what is known about the potential risk of neural tube defects when dolutegravir is used around the time of conception.

  • Hepatitis C treatment
    South Africa: Almost half of injecting drug users surveyed have contracted Hepatitis C
    Bhekisisa | 15 August 2018

    Close to half of injecting drug users surveyed in South Africa are living with the potentially deadly Hepatitis C virus, a new study has found. But a drug that could cure them, and that is used in several countries, remains unavailable in South Africa.

  • Circumcision
    Medical male circumcision: is the HIV prevention claim wrong?
    Business Day | 15 August 2018

    Circumcision is a proven intervention that reduces the chance of contracting HIV by 60%, but to scientists’ surprise, a study has found that medically circumcised older men in Mpumalanga had a higher rate of HIV than uncircumcised men.

← First12345...11Next →

Conference news

News from the 22nd International AIDS Conference (AIDS 2018).

HIV update

Sign up for HIV update, our fortnightly news bulletin for people living with HIV in the UK.

Achieving the 90-90-90 target

With advances in HIV testing, treatment and care, some countries are making great progress towards the UNAIDS 90-90-90 target.

New EUROBulletin

Read the June edition of the Sexual Health & HIV Policy EUROBulletin.

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.